Klara R Klein, Trine J Abrahamsen, Anna R Kahkoska, G Caleb Alexander, Christopher G Chute, Melissa Haendel, Stephanie S Hong, Hemalkumar Mehta, Richard Moffitt, Til Stürmer, Kajsa Kvist, John B Buse
INTRODUCTION: People with type 2 diabetes are at heightened risk for severe outcomes related to COVID-19 infection, including hospitalization, intensive care unit admission, and mortality. This study was designed to examine the impact of premorbid use of glucagon-like peptide-1 receptor agonist (GLP-1RA) monotherapy, sodium-glucose cotransporter-2 inhibitor (SGLT-2i) monotherapy, and concomitant GLP1-RA/SGLT-2i therapy on the severity of outcomes in individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection...
March 27, 2024: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders